This is the authors' abstract. We don't add key points for this paper.
Osteosarcoma, a cancer predominantly affecting children and teenagers, has shown limited improvements in long-term survival rates despite advances in treatment, necessitating new therapeutic approaches. Natural compounds, particularly flavonoids, are being investigated for their anti-cancer properties due to their ability to modulate signaling pathways and induce apoptosis in cancer cells. This study evaluates the anti-carcinogenic effects of 6,3'-dimethoxy flavonol on MG-63 osteosarcoma cells, a p53-null model suitable for testing novel therapies, using various assays. Cell viability and proliferation were measured via MTT assay, showing dose dependent inhibition with an IC50 of 221.017 µg/ml at 48 hours. Phase-contrast microscopy revealed morphological changes consistent with apoptosis, including cell shrinkage, reduced density and cytoplasmic blebbing. Wound healing assays demonstrated significant inhibition of cell migration at 100 µg/ml and 234.12 µg/ml, highlighting its anti-metastatic potential. Acridine orange/ethidium bromide (AO/EB) staining confirmed apoptotic cell death. Real-time PCR analysis revealed an increased (Bax/Bcl-2) ratio and upregulation of p53 expression, indicating activation of the intrinsic apoptotic pathway. These findings demonstrate that 6,3'-dimethoxy flavonol effectively induces apoptosis and inhibits migration in MG-63 cells by modulating apoptotic markers and signaling pathways. The results suggest its potential as a therapeutic agent for osteosarcoma. Future studies should explore itsinvivo efficacy, possible synergistic effects in combination therapies, and its mechanisms in p53-positive cell lines. This evidence underscores the promise of flavonoid based interventions in cancer treatment.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Pandi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: